The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study

Annals of Oncology

Volumn 7, Issue 7, 1996, Pages 671-675

  Chang, J ^a   Powles, T J ^a   Ashley, S E ^a   Gregory, R K ^a   Tidy, V A ^a   Treleaven, J G ^a   Singh, R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Antithrombin III; Bone mineral density; Cholesterol; Fibrinogen; HRT; Tamoxifen

Indexed keywords

ANTITHROMBIN III; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FIBRINOGEN; PREMPAK; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029833720     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010715     Document Type: Article

References (25)

1. LA Rosa JC. Has HRT come of age? Lancet 1995; 345: 76.
2. Bonadonna G, Valagussa P, Rossi A et al. CMF adjuvant chemotherapy in operable breast cancer. In Jones SE, Salmon SS (eds): Adjuvant Therapy of Cancer II. New York: Grure and Stratton Inc 1979; 227-35.
3. Cobleigh MA, Berris RF, Bush T et al. Estrogen replacement therapy in breast cancer survivors. JAMA 1994; 273: 540-5.
4. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72.
5. Steinberg KK, Thacker SB, Smith SJ et al. A meta-analysis of the effect of estrogen replacement therapy and the risk of breast cancer. JAMA 1991; 265: 1985-90.
6. Armstrong BK. Oestrogen therapy after the menopause: Boon orbain? Med J Aust 1988; 148: 213-4.
7. Fisher B, Constantino J, Redmond C et al. A randomised trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen receptor negative tumours. N Engl J Med 1989; 320: 489.
8. Pike MC, Spicer DV. The chemoprevention of breast cancer by reducing sex steroid exposure: Perspectives from epidemiology. J Cell Biochem 1993; 179 (Suppl): 26-36.
9. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant trial. The Scottish Breast Cancer Committee. Br J Cancer 1991; 303: 435-7.
10. Powles TJ, Tillyer C, Jones AJ et al. Prevention of breast cancer with tamoxifen. An update on the Royal Marsden pilot programme. Eur J Cancer 1990; 26: 680-2.
11. Love RR, Newcomb PA, Wiebe DA et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 82: 1327-32.
12. Kristensen B, Ejiersten B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients: A randomised study. J Clin Oncol 1994; 12: 992-7.
13. Powles TJ, Hickish T, Kanis JA et al. The effect of tamoxifen on bone mineral density measured by dual energy X-ray absorptiometry in healthy pre- and postmenopausal women. J Clin Oncol 1996; 14(1): 76-84.
14. Devor M, Barrett-Connor E, Ranwell M et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82.
15. Powles TJ, Hardy JR, Ashley SE et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for the prevention of breast cancer. Br J Cancer 1989; 60: 126-31.
16. Powles TJ, Jones AJ, Ashley SE et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res and Treat 1994; 31: 73-82.
17. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein and cholesterol concentration in the plasma of human subjects measured in the fed and fasting state. Clin Chem 1988; 34; 2456-59.
18. Hesse R, Tritschler W, Castelfranchi G, Bablok W. Antithrombin III: Reference values found with chromogenic substrate (chromozym TH). Blut 1981; 42: 227-34.
19. Becker U, Bart LK, Wahlefold AW. A functional photometric assay for plasma fibrinogen. Thromb Res 1984; 35: 475-84.
20. Powles TJ, Hickish T, Casey S, O'Brien M. Hormone replacement therapy after breast cancer. Lancet 1993; 342 (8862): 60-1.
21. Dahan R, Espie H, Mignot C et al. Tamoxifen and arterial thrombosis. Lancet 1985; 1: 638.
22. Lipton A, Harvey H, Hamilton KW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Res 1984; 68: 887-9.
23. Taberno MD, Tomas JF, Alberca I. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Haematol 1991; 36: 249-54.
24. Jones AJ, Powles TJ, Treleaven JF et al. Heamostatic changes and the thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992; 66: 744-7.
25. Boschetti C, Cortellaro M, Nencioni, T et al. Short and long term effects of hormone replacement therapy (transdermal estradiol vs. oral conjugated equine steroids) on blood coagulation factors in postmenopusal women. Thromb Res 1991; 62: 1-8.